Skip to content
Credit reportVerdict and grounds
Made on 18-11-2026 at 14:42
Reference CK-0799669186-20261118

4Tissue

ActivePrivate limited company0799.669.186Technologiepark-Zwijnaarde 94, 9052 Ghent
Manufacture of medical and dental instruments and supplies (NACE 32500) · founded in 2023 · accounts in the micro format

Sources: the KBO register on 18-11-2026; the National Bank, 2025 annual accounts filed on 11-06-2026; the Belgian Official Gazette, latest deed of 10-11-2026.

Credit verdict
Checked score 2025
The score, from 0 to 100, reflects the bankruptcy probability and the standing among sector peers.
Bankruptcy probability within 12 months
The median of 113 small companies in the other manufacturing sector (NACE 32) is 0.3%.
Gross margin
€327,753
-€113,482 in 2024
Net result
-€727,036
-€321,213 in 2024
Equity
€845,476
▲ 47.6% against 2024
Cash
€122,182
▼ 84.2% against 2024

Grounds

the facts the verdict rests on, each with its source
  1. In 2025, 4Tissue made a loss of €727,036.Annual accounts 2025 page 2
  2. Equity stands at €845,476, or 33.0% of the balance sheet total of €2.6m. That is more than 95% of the 840 companies in the other manufacturing sector (NACE 32).Annual accounts 2025 page 2
  3. The 2025 accounts reached the National Bank 50 days before the end of the term.National Bank, filing of 11-06-2026 page 4

Representation

The signing rule is in the deed of 21-03-2023.

Articles of association, Belgian Official Gazette of 21-03-2023, deed 23324477

Ownership

The accounts in the micro format list no shareholders. holds 3,000 shares. There are 2 other shareholders.

Deed of 21-03-2023

4Tissue · 0799.669.186 · credit report of 18-11-2026Page 1 of 5
4Tissue0799.669.186 · report of 18-11-2026

Financial situation

Annual accounts 2023 to 2025, as filed with the National Bank

Gross margin and net resultin €m

2023-0.022024-0.120250.32023-0.022024-0.32025-0.7
gross marginnet result

Equity and debtsin €m

2023202420250.81.7
equitydebts

Cashin €m

20230.0020240.820250.1
on the balance sheet date
Financial year20239 months20242025Trend
Results
Gross margin-€21,045-€113,482€327,753
Operating result-€21,045-€334,746-€771,968
Net result-€21,074-€321,213-€727,036
Balance sheet at the closing date
Equity-€6,074€572,712€845,476
Debts€12,399€1.0m€1.7m
Debts due within one year€12,399€44,764€179,111
Cash€3,940€771,689€122,182
Balance sheet total€6,325€1.6m€2.6m
Ratios
Solvency-96.0%35.7%33.0%
Liquidity0.5133.0110.66

Source: Annual accounts 2025, micro format, filed on 11-06-2026 (2026-00152983); Annual accounts 2024, micro format, filed on 23-06-2025 (2025-00164063); Annual accounts 2023, filed on 20-09-2024 (2024-00468055).

Debts rose by €681,939 in 2025, of which €100,104 to suppliers.

The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.

4Tissue states no turnover; the micro format does not require it. The gross margin, what is left after purchases, rose from -€113,482 to €327,753.

The financial year to 31-12-2023 ran for 9 months.

4Tissue · 0799.669.186 · credit report of 18-11-2026Page 2 of 5
4Tissue0799.669.186 · report of 18-11-2026

Board, signature and ownership

Position on 18-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts

Who represents the company

The signing rule is in the deed of 21-03-2023.

Articles of association, Belgian Official Gazette of 21-03-2023, deed 23324477

Board

six directors in office
Director (not named in the articles)since 25-04-2024
4-year term from 2024deed of 03-05-2024
Directorsince 25-04-2024
deed of 29-10-2026
Directorappointed by deed of 28-11-2024
deed of 28-11-2024
Directorappointed by deed of 29-10-2026
deed of 29-10-2026
Directorappointed by deed of 29-10-2026
deed of 29-10-2026
Director and chair of the boardrenewed by deed of 29-10-2026
deed of 29-10-2026
CEO and director generalappointed by deed of 23-09-2026
deed of 23-09-2026
Day-to-day managerappointed by deed of 03-05-2024
deed of 03-05-2024

Ownership and group

Shareholders

The accounts in the micro format list no shareholders. holds 3,000 shares. holds 3,000 shares. holds 3,000 shares.

Deed of 21-03-2023

Board changes

9,559 new shares, 9,091 new shares, 41,667 new shares.

Gazette, deed 26379164

(CEO) and (ceo / coo) resign. , and act as permanent representatives. appointed as CEO and director general. Board meeting of 27-05-2026.

Gazette, deed 26119186

appointed as director. acts as permanent representative. General meeting of 26-08-2024.

Gazette, deed 24168620
4Tissue · 0799.669.186 · credit report of 18-11-2026Page 3 of 5
4Tissue0799.669.186 · report of 18-11-2026

Events and comparison

The last 24 months, newest first

Amendment of the articles. General meeting of 14-10-2026.

Gazette, deed 26382984

Registered office moved to Ghent. The registered office moved to Technologiepark-Zwijnaarde 94, 9052 Gent. Board meeting of 15-10-2026.

Gazette, deed 26380300

9,559 new shares, 9,091 new shares, 41,667 new shares.

Gazette, deed 26379164

(CEO) and (ceo / coo) resign. , and act as permanent representatives. appointed as CEO and director general. Board meeting of 27-05-2026.

Gazette, deed 26119186

Annual accounts 2025 filed, 50 days before the deadline.

NBB filing

Weakest financial year. The net result drops to -€727,036, the lowest from 2023 to 2025.

Financial

Registered in the Peppol Directory. Reachable for e-invoices through 0208:0799669186.

Annual accounts 2024 filed, 38 days before the deadline.

NBB filing

Capital increase of €999,800, 4,999 new shares. General meeting of 10-02-2025.

Gazette, deed 25314139

Liquidity more than 64 times. The current ratio rises from 0.51 to 33.01.

Financial

Equity above €500,000. Equity rises from -€6,074 to €572,712.

Financial

appointed as director. acts as permanent representative. General meeting of 26-08-2024.

Gazette, deed 24168620

Comparable companies, two years later

In July 2024, 132 companies had the same profile as 4Tissue has now: small, 2 to 5 years old, solvency 30% or more and a loss of 10% of the balance sheet or more. Two years later 93.2% were still trading, 3.8% had stopped another way and 3.0% had gone bankrupt.

still trading 93.2% stopped another way 3.8% bankrupt 3.0%

In 2025, 4Tissue had a lower net result than 95% of the 838 companies in the other manufacturing sector (NACE 32).

Other findings

Peppol

Reachable for e-invoices since 20-11-2025, under 0208:0799669186.

Sanctions lists

4Tissue · 0799.669.186 · credit report of 18-11-2026Page 4 of 5
4Tissue0799.669.186 · report of 18-11-2026

Sources and method

Where each fact in this report comes from

SourceWhatDateReference
KBO registerRegistration, legal situation, activity, establishment units18-11-2026KBO 0799.669.186
National Bank of BelgiumAnnual accounts 2025, micro format11-06-20262026-00152983
National Bank of BelgiumAnnual accounts 2024, micro format23-06-20252025-00164063
National Bank of BelgiumAnnual accounts 2023 to 202320-09-20242024-00468055
Belgian Official GazetteBoard29-10-2026deed 26379164
Belgian Official GazetteBoard23-09-2026deed 26119186
Belgian Official GazetteBoard28-11-2024deed 24168620
Belgian Official GazetteArticles of association with the signing rule21-03-2023deed 23324477
Peppol DirectoryRegistration for e-invoices20-11-20250208:0799669186
Sanctions lists EU, UN, US (OFAC) and UKComparison of the name16-11-2026no match
CheckedChecked score, bankruptcy probability, credit, comparable companies17-11-2026bankruptcy model of 2 October 2026

Method

Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.

Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 17-11-2026.

Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.

Payment terms. Supplier credit is the debt to suppliers divided by the year's purchases, times 365. Customer credit is the same for what customers still owe, against turnover.

Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.

The scores and ratios are Checked's own calculations, not a credit decision.

4Tissue · 0799.669.186 · credit report of 18-11-2026Page 5 of 5